Jaguar Health, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lisa A. Conte
- Full Time Employees
- 47
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 200 Pine Street San Francisco CA United States of America 94104
- IPO Date
- May 12, 2015
- CIK
- 0001585608
- Website
- jaguar.health
- Similar Companies
- Business
- Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company that develops and commercializes novel, plant-based, non-opioid prescription medicines derived from rainforest plants for gastrointestinal distress in people and animals, including chronic debilitating diarrhea, urgency, incontinence, and cramping; it operates through Human Health and Animal Health segments targeting companion animals, production animals, HIV/AIDS patients on antiretroviral therapy, and cancer patients. The company offers Mytesi (crofelemer 125 mg delayed-release tablets), an FDA-approved anti-secretory antidiarrheal for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; Canalevia-CA1 (crofelemer delayed-release tablets), an FDA-conditionally approved prescription product for chemotherapy-induced diarrhea in dogs; and Neonorm products for calves and foals; its pipeline includes crofelemer in Phase III trials for prophylaxis of cancer therapy-related diarrhea (OnTarget trial topline results expected forthcoming) and Phase II/III for rare diseases such as short bowel syndrome and microvillus inclusion disease, as well as irritable bowel syndrome, idiopathic diarrhea, and NP-300 in Phase I for moderate-to-severe diarrhea. Founded in 2013 and headquartered in San Francisco, California, Jaguar conducts operations primarily in the United States with expansion efforts in Europe via Napo Therapeutics, an Italian subsidiary established in 2021, and supports investigator-initiated studies in the US, EU, and Middle East/North Africa; it maintains strategic relationships including a joint venture, Magdalena Biosciences, with Filament Health for mental health indications, an exclusive distribution agreement for Gelclair, and recent financial activities such as a $1.5 million registered direct offering in May 2025 and a submission to the European Medicines Agency in December 2025 regarding an EU approval pathway for Canalevia.
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases
Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Jaguar Health Compliant with Nasdaq Bid Price Rule
Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health Reports First Quarter 2026 Financials
Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
Jaguar Health Stock Surges On FDA Breakthrough Discussions For Rare Disease Therapy
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split